Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 7/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23164166 | 0.90 | MAOB (0.41) | KMT2AMAOBHSD17B10ALDH1A1KDM4E | |
| SCHEMBL23164163 | 0.90 | MAOB (0.41) | KMT2AMAOBHSD17B10ALDH1A1KDM4E | |
| SCHEMBL29705667 | 0.90 | MAOB (0.41) | KMT2AMAOBHSD17B10ALDH1A1KDM4E | |
| SCHEMBL19399867 | 0.88 | KDM4E (0.45) | KMT2AMAOBHSD17B10ALDH1A1KDM4E | |
| SCHEMBL25330748 | 0.81 | KDM4E (0.48) | KMT2AMAOBHSD17B10ALDH1A1KDM4E | |
| SCHEMBL19384300 | 0.81 | KDM4E (0.45) | KMT2AMAOBHSD17B10ALDH1A1KDM4E | |
| SCHEMBL30608685 | 0.81 | KDM4E (0.48) | KMT2AMAOBHSD17B10ALDH1A1KDM4E | |
| SCHEMBL25330745 | 0.81 | KDM4E (0.48) | KMT2AMAOBHSD17B10ALDH1A1KDM4E | |
| SCHEMBL20534991 | 0.81 | KDM4E (0.48) | KMT2AMAOBHSD17B10ALDH1A1KDM4E | |
| SCHEMBL29986418 | 0.81 | KDM4E (0.48) | KMT2AMAOBHSD17B10ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| EP-3433254-B1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-17 | — | — | EP | disclosed |
| EP-3433254-B1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-17 | — | — | EP | disclosed |
| US-20190112306-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| US-20190112306-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| EP-3433255-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-01-30 | — | — | EP | disclosed |
| EP-3433254-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017162572-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162572-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162570-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162570-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | ITGB6, ITGA6, ITGB3 | KMT2A 3273/4885MAOB 3037/4885HSD17B10 4552/4885 |
| US-20190112306-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | ITGB6, ITGA6, GP6 | KMT2A 3231/4885MAOB 3058/4885HSD17B10 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.